Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

ABL kinase signaling networks regulate Transcription-Replication Collisions in Small Cell Lung Cancer

Award Number: R01CA318002
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2031

Group Awards By:

View Award Description

ABL kinase signaling networks regulate Transcription-Replication Collisions in Small Cell Lung Cancer - Maintenance of genomic stability requires coordinated spatial and temporal regulation of the replication and transcription machineries on DNA. Deregulated transcription in cancer cells can promote transcription-replication conflicts (TRCs) through increased collisions with the replication machinery, thereby generating breaks on the DNA. Unexpectedly, we discovered that inhibition of the ABL tyrosine kinase enhances accumulation of TRCs in small cell lung cancer (SCLC), thereby revealing a novel role for ABL in the regulation of collisions between the transcription and DNA replication machineries. Notably, we found that ABL inactivation markedly impairs outgrowth of SCLC tumors in mouse models, resulting in prolonged animal survival. Further, ABL inactivation impairs the expression and function of proteins implicated in transcription-coupled homologous recombination (TC-HR). SCLC is a highly aggressive neuroendocrine lung cancer with an overall 5-year survival rate of only ~7%, which has remained unchanged for over 30 years. SCLC tumors exhibit a high degree of genomic instability with upregulation of proteins in the TC-HR pathway. TC-HR promotes repair of DNA double strand breaks (DSBs) at sites of active transcription and is associated with formation of R-loops comprised of DNA-RNA hybrids and displaced single-stranded DNA. Abnormal accumulation of R-loops increases TRCs, leading to enhanced DNA damage and cell death. Because ABL inactivation markedly increased TRCs and DNA damage, we evaluated whether blocking the activity DNA damage-repair pathways by targeting ATR in the presence of ABL inhibitors might synergize to promote SCLC cell death. We found that co-inactivation of ABL and ATR kinases induces profound synergistic inhibition of SCLC cell survival and impairs SCLC dissemination and outgrowth in mouse models. Here we will evaluate the hypothesis that ABL inactivation enhances SCLC vulnerabilities by increasing TRCs, resulting in enhanced DNA damage, and rendering SCLC cells hypersensitive to inactivation of components of DNA damage-repair pathways. The specific aims are: 1) Define the mechanisms by which ABL inactivation increases TRCs and DNA damage in SCLC subtypes. 2) Identify novel combination therapies to treat SCLC revealed by unbiased ABL inhibitor-mediated sensitization screens with SCLC cell lines, clinicalbiopsy- derived micro-organospheres, and SCLC metastases from mouse models treated with single and combination therapies. 3) Define the transcriptional landscapes of patient-derived SCLC subtypes, and metastatic SCLC in situ in mouse models treated with single and combination therapies. Justification for use of animal models: The use of mouse models is required for lung cancer metastasis studies to assess the contribution of multiple cell types, including immune cells, implicated in the metastatic cascade. There are no in vitro co-culture systems that faithfully mimic the complex interactions of SCLC metastases and cell types in the tumor microenvironment required for the multi-step process of metastasis observed in vivo. Completion of the proposed research will reveal novel mechanistic insights into pathways that promote SCLC metastasis, uncover the mechanisms whereby ABL signaling networks regulate TRCs, and reveal the effectiveness of co-inactivation of ABL kinase and DNA damage-repair pathways to impair dissemination and outgrowth of deadly SCLC tumors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $646,454 )
2026	2026	DUKE UNIVERSITY	2200 W MAIN ST	DURHAM	NC	27705	DURHAM	USA	Cancer Cause and Prevention Research	000	1	6/19/2026	NEW	$646,454
														Subtotal = $646,454

Grand Total All Awards = $646,454

Top

All Categories

About

Search

Reports

Data Submission

Award Information

ABL kinase signaling networks regulate Transcription-Replication Collisions in Small Cell Lung Cancer

Award Number: R01CA318002

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2031

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer